Praxis Medical Insights

Est. 2024 • Clinical Guidelines Distilled

Made possible by volunteer editors from the University of Calgary & University of Alberta

Last Updated: 9/27/2025

Treatment of Severe Hepatic Steatosis

Lifestyle Interventions

  • The American Association for the Study of Liver Diseases recommends achieving sustained weight loss of at least 7-10% through dietary modification and exercise, with Mediterranean-style dietary patterns and at least 150 minutes weekly of moderate-intensity physical activity being the most strongly recommended interventions 1, 2
  • Aim for >10% sustained weight reduction to improve fibrosis in patients with severe steatosis, particularly those with overweight or obesity 1, 3
  • Weight loss of 5% reduces liver fat 1
  • Weight loss of 7-10% improves liver inflammation 1, 2
  • Adopt a Mediterranean dietary pattern including vegetables, fruits, unsweetened high-fiber cereals, nuts, fish or white meat, and olive oil 1, 2, 4
  • Eliminate sugar-sweetened beverages completely 1, 2
  • Limit ultra-processed foods rich in sugars and saturated fat 1, 2
  • Prescribe at least 150 minutes per week of moderate-intensity exercise or 75 minutes per week of vigorous-intensity activity 1, 2, 5
  • Physical activity reduces steatosis even without significant weight loss 1, 4

Pharmacological Considerations

  • Resmetirom should be considered for non-cirrhotic patients with significant liver fibrosis (stage ≥2) if approved locally, as it demonstrated histological efficacy in phase III trials with acceptable safety 6, 7, 8
  • GLP-1 receptor agonists (semaglutide, liraglutide) should be used for their approved indications (type 2 diabetes, obesity) as they improve cardiometabolic outcomes and are safe in MASH, including compensated cirrhosis 7, 8, 5, 4
  • Statins are safe and should be used for dyslipidemia in patients with hepatic steatosis 4, 9

Monitoring and Risk Stratification

  • Stratify patients using FIB-4 score, liver stiffness measurement (LSM), or liver biopsy 4
  • High-risk patients have FIB-4 >2.67, LSM >12.0 kPa, or significant fibrosis on biopsy 4
  • Patients with advanced fibrosis (F3) require hepatocellular carcinoma surveillance with imaging every 6 months 9

Multidisciplinary Approach

  • A multidisciplinary approach is essential to address both liver-related and extrahepatic outcomes, given the bidirectional connections between steatotic liver disease and cardiometabolic comorbidities 2, 3
  • Screen and manage diabetes, dyslipidemia, and hypertension aggressively 4
  • Optimize glycemic control in diabetic patients to reduce liver fat 4
  • Avoid medications that worsen steatosis including corticosteroids, amiodarone, methotrexate, tamoxifen, estrogens, tetracyclines, and valproic acid 4

Special Considerations

  • Consider bariatric surgery for appropriate individuals with clinically significant fibrosis and obesity with comorbidities 4
  • Coffee consumption has been associated with improvements in liver damage and reduced liver-related clinical outcomes in observational studies 1, 2, 5
  • Weight loss through diet and exercise remains the only intervention with Level 1 evidence for improving liver injury 1, 2, 3